Adverum completes enrollment in phase 2 DME trial
Click Here to Manage Email Alerts
Adverum Biotechnologies has completed enrollment in the phase 2 INFINITY trial to evaluate a single injection of ADVM-022 for the treatment of diabetic macular edema, according to a press release.
ADVM-022 may offer a lower treatment burden than frequent, long-term anti-VEGF intravitreal injections. In the phase 1 OPTIC trial, a single in-office intravitreal injection has shown efficacy and safety for upward of 2 years in patients with wet age-related macular degeneration.
“2021 is an exciting year for Adverum as we build on the tremendous progress we have made to advance ADVM-022, a potential one-time intravitreal injection gene therapy for VEGF-driven retinal diseases, into a pivotal trial for wet AMD and in phase 2 for DME. ADVM-022 has the potential to help millions of patients at risk of losing their vision,” Laurent Fischer, MD, CEO of Adverum, said in the release.
Adverum expects to present clinical data from the INFINITY trial later this year.
Click Here to Manage Email Alerts